

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Zhongzhi Pharmaceutical Holdings Limited**

**中智藥業控股有限公司**

*(Incorporated in Cayman Islands with limited liability)*

**(Stock Code: 3737)**

### **POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 13 OCTOBER 2017**

The Board is pleased to announce that the resolution proposed at the EGM held on 13 October 2017 was duly passed by the Shareholders by way of poll at the EGM.

The board of directors (the “**Board**”) of Zhongzhi Pharmaceutical Holdings Limited (the “**Company**”) is pleased to announce that the proposed resolution as set out in the notice of extraordinary general meeting of the Company dated 20 September 2017 was duly passed by the shareholders of the Company (the “**Shareholders**”) by way of poll at the extraordinary general meeting of the Company held on 13 October 2017 (the “**EGM**”).

As at the date of the EGM, the total number of shares in the issued share capital of the Company was 800,000,000 shares. None of the Shareholders were required to abstain from voting at the EGM. Accordingly, there were a total of 800,000,000 shares, representing the entire issued share capital of the Company, entitling the Shareholders to attend and vote for or against the resolution proposed at the EGM.

The Company’s branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of votetaking.

The poll results in respect of the resolution at the EGM are set out as follows:

ORDINARY RESOLUTION		Number of votes (%)	
		FOR	AGAINST
1.	<p>(a) the declaration and payment of an interim dividend of HK1.875 cents per ordinary share out of the share premium account of the Company (the “<b>Interim Dividend</b>”) to shareholders of the Company whose names appear on the register of members of the Company on the record date fixed by the board of Directors for determining the entitlements to the Interim Dividend be and is hereby approved; and</p> <p>(b) any Director of the Company be and is hereby authorised to take such action, do such things and execute such further documents as the director may at his absolute discretion consider necessary or desirable for the purpose of or in connection with the implementation of the payment of the Interim Dividend.</p>	586,402,000 (100.00%)	0 (0.00%)

As more than 50% of the votes were cast in favour of the resolution, such resolution was duly passed as ordinary resolution of the Company.

By order of the Board  
**Zhongzhi Pharmaceutical Holdings Limited**  
**Mr. Lai Zhi Tian**  
*Chairman and Executive Director*

Hong Kong, 13 October 2017

*As at the date of this announcement, the Board comprises eight directors. The executive directors are Mr. Lai Zhi Tian, Ms. Mou Li, Mr. Cao Xiao Jun and Mr. Cheng Jin Le. The non-executive director is Ms. Jiang Li Xia. The independent non-executive directors are Mr. Ng Kwun Wan, Mr. Wong Kam Wah and Mr. Zhou Dai Han.*